Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company’s lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101’s anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The Company has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. It anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101. It has conducted Phase III trial.
Summary I'm really not sure what's going on here. It's not really a sideways move after the explosive move. Instead, it's melting up. I'm not sure if that's good or bad but doesn't seem right. My gut tells me to take it off the watchlist,…
This checks most of the boxes for a Power Play. My biggest concern is that we aren't in a bull market. Power Plays can still work in bear markets, but they are less likely. However, this is in the Health Care sector, which has been…